Global Oral Contraceptive Pills Market to be worth US$22.9 bn by 2023, Increasing Awareness Regarding Benefits of Contraceptive Pills Drives Growth

The opportunity in the global oral contraceptive pills market was reported to be US$13.1 bn in 2014 and is anticipated to be worth US$22.9 bn by 2023, registering a steady CAGR of 6.6% therein.

Oral Contraceptive Pills Market: Snapshot

The highly competitive oral contraceptive pills market is marked by the presence of several generic product manufacturers, most of which resort to price reduction and free samples to sustain in the market. Oral contraceptive pills are the most common form of reversible contraception in most developed economies of the world, such as Western Europe, the U.S., Canada, and Australia. The adoption and prescription pattern for oral contraceptive pills varies by region, price, and level of awareness and companies have been taking these factors into consideration to up their share in the market.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/oral-contraceptive-pills-market.htm

Generic Oral Contraceptive Pills Enjoy Larger Share in Global Market

By type of product, the oral contraceptive pills market has been segmented into progestin-only, combination, and others. The combination oral contraceptive pills segment led the overall market in 2014 and is projected to register the highest growth rate over the course of the forecast period. This growth can be attributed to their higher efficiency in preventing pregnancies, their easy availability, and their rising preference among consumers.

On the basis of category, the market is bifurcated into generic oral contraceptive pills and branded pills. In 2014, generic oral contraceptive pills led the overall market and this segment is projected to record the fastest growth rate by 2023. The growth of this segment can be attributed to the widespread adoption of generic contraceptives facilitated by their low prices and ease of use.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8323

Favorable Reimbursement Policies in U.S. Spur Adoption of Oral Contraceptive Pills in North America

The global contraceptive pills market is geographically segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. North America led the global contraceptive pills market in 2014 primarily owing to a greater incidence of unintended pregnancies in the region. The Centers for Disease Control and Prevention (CDC) states in a study that between 2006 and 2010, a 37% of the total pregnancies in the U.S were unintended. A significant proportion of these pregnancies led to abortions, which resulted in a massive yet preventable healthcare expenditure. In a bid to curb this avoidable healthcare expense, the governments of North American countries are encouraging women to opt for modern and more effective contraceptive options. The enforcement of the Affordable Care Act, or Obamacare, in the U.S. and various awareness programs by non-profit organizations have led to the availability of favorable reimbursement policies and the increased sale of emergency oral contraceptive pills in the region.

Asia Pacific is viewed as one of the most attractive market for oral contraceptive pills in the course of the forecast period thanks to the steady economic development in countries such as Singapore, India, China, Australia, and Philippines. This economic growth has resulted in the increasing disposable income of the people, surging awareness about family planning and contraceptives, and the desire for healthier living. This, in turn, has led to the rising adoption rate of oral contraceptive pills in the region.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8323

The leading players competing in the global oral contraceptive pills market include Bayer AG, Janssen Global Services, LLC, Allergan,plc (Actavis), Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Pfizer, Inc., Merck & Co., Inc., and Mankind Pharma Ltd.

Global Non-Small Cell Lung Cancer Therapeutics Market to Reach US$15.1 bn by 2023, Asia Pacific to Report Fastest CAGR

A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer (NSCLC) therapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period.The report, titled “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” states that the worldwide NSCLC market attained US$4.9 bn in 2014.

Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.

Read Full Report: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study.

Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities

Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come.

Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis

On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.

On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years.

Companies Mentioned in the Research Report

Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world.

Global Cell Culture Market to Reach US$11.3 bn by 2022 due to Rising Demand in Stem Cell, Cancer Research

The global cell culture market is currently dominated by three major companies who together hold 52% of the market share. Thermo Fisher Scientific ranks on top with 32.9% of the market share, followed by BD Biosciences and EMD Millipore respectively. BD Biosciences has a strong presence in developed economies such as EU5 nations and U.S. Sigma-Aldrich is also a key player in the cell culture consumables business such as media, reagents, and sera. Corning Life Sciences offers economical platforms as compared to other companies. The report finds that high product differentiation plays a major role in determining the market position of the players. A large number of small players are entering the market too, especially in emerging economies, and the outsourcing of cell culture processes to cell culture companies has also increased the competition.

The global cell culture market was valued at US$6.0 bn in 2013 and is projected to reach US$11.3 bn by 2022, expanding at a CAGR of 7.1% during the forecast period.

Geographically, North America accounted for US$2.2 bn in 2013 and is expected to continue as the primary market for cell culture. Asia Pacific is projected to experience the strongest overall growth rate. By product type, consumables had the most significant demand valuation at US$3.4 bn in 2013 and the pattern is anticipated to continue.

Massive Investments Driving Cell Culture Market

Numerous sectors such as research, bioprocessing and manufacturing, academics, and regenerative medicines use cell culture, which has led to a growing demand for these products. As a result, leading pharmaceutical companies are now focusing on increasing their capabilities into biopharmaceutical manufacturing by entering into alliances with biotech companies. For instance, Thermo Fisher Scientific acquired Life Technologies in February 2014 to establish a stronghold over the cell culture market.

Massive capital investments and specificity of each bio-manufacturing process is leading to a shift toward contract manufacturing and research. Furthermore, the expanding scope of cell culture in areas such as stem cell research is also proving to be a positive influence on the market.

Artificial organs are engineered biological substitutes used to replace the structure and restore the functions of an impaired or diseased organ. The market for artificial organs is projected to expand at a double-digit CAGR during the forecast period. Moreover, the trend toward serum-free, specialty and customized media solutions is expected to boost market growth and the applicability of cell culture technology.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405

Demand for Advanced Manufacturing Capabilities to Fulfill Requirements

The process of cell culture is complex and requires monitoring several parameters such as temperature, humidity, nutrients, and toxins. Any deviation from the precise handling technique could have an impact on the efficacy of the end product. These constraints are expected to bottleneck the process of cell culture development and manufacturing.

Moreover, the growth of the cell culture market is also likely to be affected by the development of alternative technologies such as transgenic animals and plants for biopharmaceutical production. Ethical concerns over the use of animal sources is another aspect that may curtail the cell culture market growth.

“Cell culture model systems in drug discovery and drug evaluation is opening up significant possibilities for market growth and 3D cell culture is acting as a future opportunity in in vitro analysis too,” reveals the author of the report.

The information presented in this review is based on a Transparency Market Research report, titled, “Cell Culture Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022.”

Healthcare Cleanroom Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

With a large pool of manufacturers, the healthcare cleanroom consumables market demonstrates a fragmented structure and experiences a high degree of competition, finds Transparency Market Research (TMR) in a new study. In 2014, the top five participants, namely, Kimberly-Clark Corp., Texwipe, Nitritex Ltd., Valutek, and DuPont, collectively held a share of just 52% in the overall market.

The rivalry among players has resulted in less differentiation in products and their pricing structures. However, companies can generate weighty profits by focusing on commercial and cost-efficient consumables such as wipers, gloves, and apparels such as aprons, boot covers, sleeves, bouffant, masks, and shoe covers, which are highly utilized in hospitals, laboratories, and research centers.

Healthcare Cleanroom Consumables Sales Gain Momentum from Escalating Demand for Drugs and Medical Devices

The increased prevalence of a number of diseases, such as cancer, diabetes, respiratory disorders, cardiovascular diseases, and several genetic ailments has fueled the demand for drugs and technically advanced medical devices for the detection and the treatment of these diseases. As cleanrooms allow to maintain low levels of pollutants such as dust, chemical vapors, and microorganisms, upholding the quality of production, the application of cleanrooms and cleanroom consumables has increased significantly in the production of medicines as well as medical equipment. Their demand is also witnessing a remarkable rise due to the increase in research activities in the medical and healthcare industry.

Apart from this, the growing number of medical device manufacturers is also leading to a significant rise in the number of cleanrooms for the production of electronic components as well as devices for medical utilization. Stringent regulatory policies and frequent device recalls have compelled manufacturers to focus specifically on the quality of their products, leading to the need for cleanroom consumables.

Going forward, with China emerging as a cheap electronic component and medical devices manufacturing hub and India becoming the preferred location for the production of generic drugs and active pharmaceutical ingredients, Asia Pacific is projected to present most promising opportunities in healthcare cleanroom consumables over the next few years.

Asia Pacific to Witness Substantial Rise in Demand for Healthcare Cleanroom Consumables

“The global market for healthcare cleanroom consumables will witness a substantial rise in the forthcoming years,” states an analyst at TMR. Registering a healthy CAGR of 4.76% from 2015 to 2023, the opportunity in healthcare cleanroom consumables is projected to increase from a value of nearly US$2 bn in 2014 to be worth US$3 bn by the end of the forecast period.

In 2014, North America led the demand for healthcare cleanroom consumables with a share of 34% and was closely followed by Europe, which held a share of 30%. Both regions are likely to retain their market shares as well as positions until the end of the forecast period. Asia Pacific, on the other hand, is projected to witness a substantial rise in its total share by 2023.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8227

Biotechnology has emerged as the biggest application area of healthcare cleanroom consumables and is expected remain the same in the coming years. Gloves will continue to be the most demanded consumables across the world in the near future.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Healthcare Cleanroom Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Key Takeaways

• Intense rivalry among players has resulted in less differentiation in healthcare cleanroom consumables and their pricing structures
• Growing number of medical device manufacturers is leading to a significant rise in the number of cleanrooms
• Opportunity in healthcare cleanroom consumables is likely to expand at a CAGR of 4.76% from 2015 to 2023

Global Cell Culture Market: Growing Demand for Artificial Organs to Pave Way for Market’s Growth

The vendor landscape in the global cell culture market includes players such as VWR International LLC, Thermo Fisher Scientific Inc., GE Healthcare, Lonza Group Ltd., Becton, Dickinson & Co., Sigma-Aldrich Co. LLC., Corning Life Sciences B.V., EMD Millipore, PromoCell GmbH, and Wheaton Industries Inc. According to a TMR analyst, mergers and acquisitions among the key players are expected to strengthen the market in the coming years.

Cell Culture Consumables Register Higher Demand than Serums and Reagents

The market players are registering increased demand for cell culture across the medical research sector. Cell cultures are being increasingly applied across drug screening and monitoring, disease diagnosis, biologic manufacturing, IVF technology, cancer research, and stem cell research. Increased investments by private medical organizations and government organizations have supported the growth of the global cell culture market. TMR states that among the cell culture consumables, cell culture media register the highest demand compared to serums and reagents. This is due to the key importance of the nature of the culture medium to the health of the cells.

3D Cell Culture to Define Future of Global Cell Culture Market

The growing demand for biopharmaceuticals and artificial organs, coupled with the emerging trend towards serum-free, customized and specialty media solutions is the primary factor contributing towards the growth of the global cell culture market. The increasing focus on stem cell research would further expand the scope of the market in future. TMR recommends that the focus on backward integration to conduct in-house research and sustaining pricing pressures amid a weak global economic scenario will open up significant opportunities for the market players.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405

However, ethical concern over the usage of animal sources in cell culture is one of the major restraints in the growth of the market. The usage of transgenic plants and animals, and stringent process controls will also impede the growth of the market in the years to come. “3D cell culture has the potential to serve as the future growth opportunity for the market and in vitro analysis.” a TMR analyst predicts.

Asia Pacific to Register Highest Demand for Cell Culture

TMR predicts that among the key regions in the global cell culture market, Asia Pacific will register the fastest growth during the period between 2014 and 2022. “The improvement in economic conditions of the developing countries in the Asia Pacific region such as China and India is anticipated to support the market’s growth,” the analyst states. In 2013, North America was the leading region in the market.

TMR finds that the various opportunities in the global cell culture market will propel the expansion of the market at a CAGR of 7.1% during the period from 2014 to 2022. This would lead to an increase in the valuation of the market from US$6.1 bn in 2013 to US$11.3 bn in 2022.

The review is based on the conclusions of a TMR report titled “Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022.”

Continuous Glucose Monitoring Market Outlook and Forecast up to 2019

Continuous glucose monitoring systems (CGMS) are portable and real-time glucose monitoring systems employed for glucose level measurement from time to time from the body of a patient. These systems make use of a wireless technology for the transmission of glucose readings which are taken from the interstitial fluid of the skin cells of the patient, unlike the measurement of glucose levels present in the blood which happens in case of blood glucose meters. The swiftly increasing diabetic population globally has substantially raised the preference for effectual diabetes management systems.

Transparency Market Research (TMR), a market intelligence company, studies the continuous glucose monitoring market in detail. It provides the reasons behind their increased demand and the type of devices leading the market.

Research Report:

http://www.transparencymarketresearch.com/continuous-glucose-monitoring.html

Q. Why are CGMS gaining popularity over the conventionally utilized glucose monitoring systems?

The utilization of CGMS is immensely rising and they are overtaking the conventionally utilized glucose monitoring systems owing to them being user friendly, more accurate, and their provision of presenting access to real-time trends and values. In addition, continuous glucose monitoring systems aid in the management of diabetes, particularly in patients having diabetes I and also aid in lowering long-terms complexities related to diabetes. Furthermore, the increasing technological innovations are also amongst the prime factors behind the increasing employment of these systems, making the control and management of diabetes mellitus relatively simpler. The early identification of hypoglycemic and hyperglycemic levels by the utilization of CGMS devices will also fuel their demand over other types of blood glucose monitoring systems.

Q What are the key opportunities and which factors may negatively impact the growth of the market?

There are numerous growth opportunities in the market as a number of companies have made investments in the research and development of CGMS, thus making the management and control of diabetes easier. For instance, Dexcom, Inc. has developed the next generation disposable continuous glucose monitoring device and it will be introduced in the market by 2021. This launch will positively impact the growth of the market. In addition, the artificial pancreas’ approval, which makes the utilization of CGMS mandatory has also emerged as a key opportunity in the global continuous glucose monitoring devices market. However, the dearth in the reimbursement options and the strict regulatory norms in some nations are amongst the crucial factors impeding the growth of the continuous glucose monitoring market.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1169

Q. Which device/brand and region have dominated the market?

The segment of Guardian Real Time CGM System led the market in 2012 and was trailed by Dexcom Seven Plus CGM system. On the other hand, in the forecast horizon between 2013 and 2019, the development of the segment of FreeStyle Navigator will witness immense growth.

Geographically, North America held a dominant share in the market for CGMS on the basis of revenue in 2012. This is due to the increasing geriatric population, the increasing obesity, and the growing acceptance of cutting-edge devices in this region. North America was trailed by Europe, which was further followed by Asia Pacific, constituting the third position in the market. In addition, Asia Pacific is predicted to hold the most lucrative opportunities in the growth of the market in forthcoming years.

APAC Market for Lateral Flow Diagnostic Tests to Exhibit 5.70% CAGR between 2015 and 2023

Lateral flow diagnostics have emerged as key diagnostics tests in recent years due to a high prevalence of cardiovascular diseases, rising cases of cancer, and growing number of diabetic patients. The leading players in the Asia Pacific lateral diagnostic tests market such as Alere, Inc., Beckman Coulter, Inc., Becton Dickinson, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. are focusing on intensifying their research and development activities to develop point-of-care testing methods are deliver accurate test results.

In August 2016, Alere Inc. stated that it was awarded the In-Vitro Diagnostic (IVD) CE marking in Europe. The company will now be able to use its Alere™ Reader, a diagnostic analyzer for laboratory and point-of-care testing across Europe. The new analyzer is expected to ensure accurate test results within an actionable time period to provide the right treatment to the patient. Though the launch is initially in Europe, the product will come to other regions of the world in the near future.

Q. What are the prominent drivers in the APAC market?

A. The sudden outburst of infectious diseases along with chronic conditions are expected to drive the Asia Pacific lateral flow diagnostic tests market in the coming years. The growing awareness about healthcare and the availability of a wide range of diagnostics are also anticipated to fuel the overall market. According to the latest report published by Transparency Market Research, the opportunity in the APAC lateral flow diagnostic tests market is expected to be worth US$3.22 bn by 2023 as compared to US$2.30 bn in 2015. Between the years of 2015 and 2023, the overall market is expected to rise at a CAGR of 5.7%.

Q. Which application segment is poised to emerge as a leading segment in the APAC lateral flow diagnostic tests market?

A. The lateral flow diagnostic tests are primarily used for diagnosing pregnancy as the awareness about pregnancy testing is growing in the remote regions of Asia Pacific. Growing number of pregnancies and affordability of these tests are some of the factors that are expected to augment the demand for lateral flow diagnostic tests for pregnancy. Analysts predict that application of lateral flow diagnostic tests for pregnancy will rise at a CAGR of 4.5% during the forecast period.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7739

Q. Which region is set to dominate the overall market by the end of the forecast period?

A. Japan is anticipated to be the frontrunner in the APAC lateral flow diagnostics market due to the revolutionary work by some of its Universities in developing diagnostics for Ebola. For instance, researchers at Nagasaki University are focusing on developing cost-effective diagnostic kits for testing Ebola. An effort such as this is projected to put this region in the lead. The rise of Japan in the APAC lateral flow diagnostic tests market will also be supported by the growing expenditure on healthcare and improving infrastructural developments that are permitting citizens a smoother access to medical help.

India and China are also expected to be the emerging countries due to their mammoth population bases. The changing faces of the healthcare sector, rising cases of obesity, poor dietary habits, and changing lifestyles are all expected to contribute towards increased uptake of lateral flow diagnostic tests in these countries. Furthermore, the emergence of new vendors designing modern lateral flow diagnostic test kits along with growing foreign investments and collaborations with bigger players will also boost the market in these countries and in the overall region as well.

Small Bone and Joint Orthopedic Devices Market - Some Predictions for Next Few Years

The growing prevalence of degenerative disorders, such as osteoarthritis and osteoporosis, has been fuelling the demand for small bone and joint orthopedic devices significantly across the world. In 2014, the global opportunity in these devices was worth US$4.1 bn. Expanding at a CAGR of 8.10% during the period from 2015 to 2023, it is likely to reach US$8.2 bn by the end of 2023.

The rising demand for radial head repair devices and three-piece mobile ankle arthroplasty and the growing popularity of shoulder arthroplasty devices are likely to drive the market’s growth in the coming years.

North America to Remain Key Contributor to Small Bone and Joint Orthopedic Devices Market

Based on region, the worldwide market for small bone and joint orthopedic devices has been segmented into Europe, North America, Latin America, Asia Pacific, and the Middle East and Africa. Among these, North America occupied the leading position in 2014 with a share of 46.9%.

The increasing number of orthopedic procedures, the rise in the obese population, and continual introduction of technically advanced products has boosted the sale of these devices in this region over the recent past. Although the future of these devices looks good in this region, its market share, however, is likely to decline a little over the forecast period, reaching 46.5% by 2023. Despite the decline, North America will remain the key contributor to the overall market in the coming years, states TMR.

Asia Pacific, on the other hand, is projected to present the most lucrative opportunities for small bone and joint orthopedic devices in the near future on account of the improving economy of several Asian countries, which is anticipated to boost the healthcare infrastructure in the region. Apart from this, the increasing disposable income of people in this region has enabled them to afford expensive treatments, which is also expected to act as a key driving force behind the growing demand for these devices in Asia Pacific over the years.

The opportunity in small bone and joint orthopedic devices in North America is estimated to reach US$3.8 bn by 2023, whereas Asia Pacific is projected to register the fastest CAGR of 8.40% between 2015 and 2023.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3952

Demand for Small Bone and Joint Orthopedic Devices to Remain High in Shoulder Reconstruction

Shoulder reconstruction reports the most prominent demand for small bone and joint orthopedic devices across the world. The increasing shift of preferences from partial and resurfacing shoulder implants to reversed shoulder implants among patients suffering from large rotator cuff tears has emerged as the primary factor that has fueled the application of these devices in shoulder reconstruction. Along with this, the rising usage of stemless shoulder implants for the treatment of young patients is also stimulating the demand for these devices in this segment. The opportunity for small bone and joint orthopedic devices in shoulder reconstruction is expected to expand to US$4.7 bn by 2023.

The leading manufacturers of small bone and joint orthopedic devices across the world are Flower Orthopedics, Z-Medical GmbH + Co. KG, Arthrex Inc., Tecomet Inc., Wright Medical Group N.V., F. Hoffmann-La Roche Ltd., Depuy Synthes, Smith & Nephew plc, Stryker Corp., Zimmer Biomet Holdings Inc., Acumed LLC, and DJO Global.

Continued Research Makes Biotherapeutics Cell Line Development Market a Highly Attractive Space

Over the past few years, the demand for biotherapeutics has witnessed a significant rise, thanks to the increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, cancer, and multiple sclerosis. This growth in the demand for biotherapeutics, together with the imminent launch of several biopharmaceutical drugs, has created a substantial demand for cell line development.

On the other hand, the strict rules and policies, regulating cell culture procedures in the production of biotherapeutics are creating difficulties for participants in their business expansion. However, unmet medical needs in emerging economies of Asia Pacific, Latin America, and Africa, is expected to provide lucrative opportunities for market players over the next few years.

The global market for is estimated to with the opportunity in biotherapeutics cell line development will rise from US$56 mn in 2014 to nearly US$100 mn by 2022, rising at a CAGR of 7.50% between 2015 and 2022.

Asia Pacific to Provide Potential Opportunities for Cell Line Development in Biotherapeutics

North America has acquired the leading position in the worldwide market for biotherapeutics cell line development. In 2014, the opportunity in this region stood at US$23.5 mn, which is likely to increase to US$41 mn by the end of 2022. The presence of a large pool of leading biopharmaceutical companies has stimulated the biotherapeutics cell line development activities in this region, leading to remarkable growth in the market. The increasing base of geriatric population in this region is also presenting huge opportunities for the development of cell lines in biotherapeutics.

Europe, which emerged second in this market in 2014, is expected to report steady growth in the near future, thanks to the rising demand for biotherapeutics. The future of cell line development in biotherapeutics, however, lies in Asia Pacific, which stood at third position in 2014. The potential that this region holds can be understood by the fact that Asia Pacific is expected to register the fastest CAGR of 9.40% during the forecast period. The unmet medical needs and the increasing investments by major pharma companies is projected to amplify the development of biotherapeutics cell line in this region.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

Transfection and Selection to Report Higher Growth Rate in Near Future

Single cell cloning and transfection and selection are the two main processes for biotherapeutics cell line development. Single cell cloning led the market with a share of 96% in 2014. The growing adoption of instruments such as FACS and ClonePix has added significantly to the growth of single cell cloning in the recent times.

Although the single cell cloning segment is likely to remain leading throughout the forecast period; the transfection and selection segment with register a higher growth rate in the coming years, owing to the increase in the demand for monoclonal antibodies.

The top two players in the global biotherapeutics cell line development market are Becton Dickinson and Co. and Beckman Coulter. Boehringer Ingelheim Pharma GmbH & Co KG., CMC Biologics, Catalent Inc., Lonza Group Ltd., ProBioGen AG, Partec, SAFC, Sony Biotechnology Inc., Selexis SA, and Thermo Fisher Scientific Inc. are some of the other prominent market participants.

Radiofrequency Ablation Devices for Pain Management Market size and Key Trends in terms of volume and value 2015-2023

Radiofrequency (RF) ablation is a minimally invasive surgical procedure that involves a local anesthetic and mild sedation. This procedure is primarily used to reduce chronic low-back and neck pain caused due to degeneration of joints (due to arthritis and other spinal conditions). The procedure involves heating a small area of nervous tissue under controlled temperature. This results in blockage of pain signals transmitting from that area, thereby relieving the patient from chronic pain. The global RF ablation devices for pain management market was valued at US$ 358.7 Mn in 2014 and is projected to reach US$ 1,087.9 Mn by 2023 at a CAGR of 12.9% during the forecast from 2015 to 2023. The global radiofrequency ablation devices for pain management market has been broadly segmented on the basis of product type (capital equipment, reusables, and disposables) and geography (North America, Europe, Asia Pacific, Latin America, and Rest of the World).

Over the years, several techniques have been used to selectively destroy nervous tissue in the spinal axis, brain, and other locations in the body. However, the radiofrequency ablation devices have been proven to be the most effective and widely adopted technique to achieve pain relief for longer durations. The revolutionary changes in technology are being reflected through products such as cooled radiofrequency technology platforms which allow creation of larger lesions without excessive heating at the electrode. For instance, COOLIEF Cooled RF System from Halyard Health, Inc. (formerly Kimberly-Clark Health Care) can be used for pain management of hip, knee, cervical, thoracic, sacroiliac, transdiscal, and lumbar pain.

The global radiofrequency ablation devices for pain management market have been categorized into three segments based on type: capital equipment, reusables, and disposables. The capital equipment, i.e., RF generators are utilized to provide heat energy to destroy selective nerves carrying pain impulses from the affected organ. Products in the reusables and disposables segment are priced less in terms of US$, but garner substantial revenue in the global RF ablation devices for pain management market owing to high volume sales. These products are initially provided as part of ablation device package, but can be procured separately.

Geographically, North America held the largest share in the global radiofrequency ablation devices for pain management market in 2014, while Europe was the second largest regional market. One of the major factors responsible for the continued growth in these markets include aging population more susceptible to arthritis. According to a report by the World Health Organization, growth rate of aging population is expected to be higher in developed nations, especially in the U.S., Japan, and several countries in Europe. Hence, the market for RF ablation devices for pain management in North America and Europe will continue to progress at a healthy growth rate during the forecast period from 2015 to 2023.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=985

Asia Pacific will be the growth driver for global radiofrequency ablation devices for pain management market in the near future. According to the World Bank, India is likely to record the strongest economic recovery among other major developing nations from 2013 to 2016. The country is expected to witness a growth rate of 7.1% in 2016, up 2.3% from 4.8% recorded in 2013. China’s economic growth has been more than 7.5% during 2013 and is expected to continue at a similar rate in future as well. This economic growth is expected to increase the disposable income of the patient population and in turn increase the health care expenditure on novel therapies such as radiofrequency ablation devices. The rapidly aging population in Japan is also likely to contribute to the growth of the market in the region during the forecast period from 2015 to 2023.

Global Healthcare Mobility Solutions Market Driven by Rising Number of Mobile Devices and Presence of High-speed Internet Connectivity

In recent years, mobility has emerged as a crucial technology for the healthcare industry, as it enables the medical community to adopt a patient-centric approach, minimizing healthcare costs and the implications of the shortage of nursing and healthcare professionals. Increasing penetration of smartphones, tablets, and PDAs coupled with the growing focus on patient-centric applications is driving the healthcare mobility solutions market. Furthermore, advancements in network technologies (3G and 4G) and a shortage of nursing staff and healthcare professionals is expected to have a positive impact on the growth of the healthcare mobility solutions market. The security and privacy issues and interoperability challenges associated with the mobility solution have somewhat limited the widespread adoption of healthcare mobility solutions.

In terms of product and services, the mobile devices segment was the largest contributor to the global healthcare mobility solutions market in 2014 and is expected to remain the dominant product segment over the forecast period. The dominance can be attributed to increased penetration of mobile computers, smartphones, RFID scanners, tablets, and PDAs, which help healthcare service providers adopt a patient-centric approach and streamline their workflow. However, mobile applications are expected to witness the maximum adoption over the forecast period, expanding at a CAGR of 25.8%. In 2014, the enterprise solutions segment was the largest application segment, accounting for 53.1% of the market revenue. Factors such as increasing focus on healthcare cost savings and a rising demand for home healthcare services are collectively expected drive the growth of mHealth applications over the forecast period.

The healthcare service providers segment, covering hospitals, laboratories, and other healthcare facilities, was the largest end-use segment, accounting for 45.4% of the global market revenue in 2014. It is expected to remain the largest end-use segment throughout the forecasted period. However, the patients (individuals) segment is expected to exhibit the maximum growth, expanding at a CAGR of 25.8% over the forecast period. The expected growth can be attributed to increasing health awareness among consumers, availability of smart healthcare devices, and the rise in healthcare spending by consumers.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4773

Increased Accessibility to Mobile Devices and the Internet Propels Market

A research undertaken by Alego Health, a U.S.-based healthcare IT services and solutions provider, over 72% nurses and 62% doctors in the U.S. were using smartphones and tablet computers in healthcare settings in 2012. The study also states that nearly 247 mn people in the U.S. in the same year downloaded mobile healthcare apps for personal use. By that year, over 40,000 healthcare mobile apps were available in the market, the number of which has consistently increased ever since.

The high rate of adoption of mobile devices in healthcare facilities, the unprecedented pace at which technological advancements are taking place in the field of mobile connectivity, and the improved network of high-speed Internet across the globe are the key factors propelling the healthcare mobility solutions market.

North America was the largest healthcare mobility solutions market, accounting for 44.6% of the global revenue in 2014. Over the forecast period from 2015 to 2023, it is expected to retain this position owing to the established healthcare and communications infrastructure in the region. Asia Pacific is expected to witness maximum growth over the forecast period from 2015 to 2023, expanding at a CAGR of 28.3%. Some of the leading players in the market are McKesson Corporation (the U.S.), Cerner Corporation (the U.S.), Koninklijke Philips N.V. (The Netherlands), SAP SE (Germany), Oracle Corporation (the U.S.), AT&T, Inc. (the U.S.), and Cisco Systems, Inc. (the U.S.).

Radiopharmaceuticals Market Witnesses Rising Demand and Investment from R&D Activities

Transparency Market Research has announced the release of a new market research report examining the global radiopharmaceuticals market. The report analyzes historical statistics concerning the market and dominant market trends affecting the dynamics and future alteration of the market. It breaks down the market by various criteria for a comprehensive understanding of the market and profiles major companies operating in the global radiopharmaceuticals market to provide an understanding of the competitive landscape of the market.The report, titled “Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”, puts the market statistics regarding radiopharmaceuticals under the microscope in a variety of ways. It analyzes the supply chain analysis of the global radiopharmaceuticals market to understand the dynamics of the market and examines the impact analysis of the various major factors that govern the market’s development both positively and negatively.

Thus, the report will help clients identify potential barriers and formulate market strategies keeping those in mind, indicate emerging and monopoly markets to invest in, and help conceptualize the development of total solutions.The report identifies the growing incidence of cancer and increasing preference for extremely specific remedies targeted at particular conditions as the major growth drivers for the global radiopharmaceuticals market. Cancer therapeutics involving radiopharmaceuticals are a major trend expected to propel the growth of the market thanks to the increased ease it offers to the patient, particularly in contrast with the conventional chemotherapy. In addition, increasing use of radiopharmaceuticals in molecular imaging is also helping the global radiopharmaceuticals market grow at a healthy rate.

The global radiopharmaceuticals market was worth US$3.8 billion in 2011 and is expected to be growing at a stupendous CAGR of 18.3% to reach a value of US$12.2 billion by 2018.This high growth rate is calculated taking into account various market restraints such as the stringent regulatory frameworks that regulate the storage and usage of radiopharmaceuticals all over the world, a global shortage of supply, and the strengthening threat from substitute treatments.The report categorizes the global radiopharmaceuticals market on the basis of the end user applying the radiopharmaceuticals, the application of the radiopharmaceuticals, and the geographical distribution of the global market. It also categorizes the radiopharmaceutical generator market on the basis of the radioactive isotope used in it.Mo-99/Tc-99m generators took up an overwhelmingly dominant share of the global radiopharmaceuticals market, leading other segments such as Sr-82/Rb-82 generators, Ge-68/Ga-67, 68 generators, Sr-90/Y-90 generators, and W-188/Re-188 generators.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

“The technetium isotope Tc-99m has established marketing channels in the global market but the other segments are expected to make heavy inroads into the dominance of Tc-99m generators in the forecast period. In fact, all other segments of generators are expected to grow at double-digit CAGRs during the forecast period,” a TMR analyst said.

According to application, the global radiopharmaceuticals market is divided into the use of radiopharmaceuticals for diagnosis, which includes the techniques of SPECT and PET and has applications in oncology, cardiovascular disorders, and others such as neurology and gastrointestinal disorders; and the use of radiopharmaceuticals for therapy, inclusive of the various isotopes used in cancer treatment and the treatments used in other types of disorders such as cardiovascular and neurological. Oncology dominates the global market for radiopharmaceuticals comprehensively.

Epidermal Growth Factor Receptor Antibodies Market Outlook and Forecast up to 2023

The epidermal growth factor receptor (EGFR) is defined as a transmembrane tyrosine kinase receptor involved in the survival and proliferation of the cancerous cells. Any kind of mutations affecting these EFGR receptors or activity could results in cancer. Mutations lead to over-expresion resulting in large number of cancer, including lung cancer, anal cancer and glioblastoma multiforme. EGFR receptors are the first molecule target against which monoclonal antibodies (mAb) have been designed for cancer treatment. These monoclonal antibodies are sometimes also referred as EGFR antibodies. EGFR antibodies market can be segmented on the basis of the major antibodies which are used against EGFR receptors which include:

• Cetuximab
• Panitumumab
• Nimotuzumab

Cetuximab (erbitux) and panitumumab (vecitibix) are the most preferred biosimilar EGFR antibodies which are used for treatment of cancer. These antibodies have demonstrated efficacy in the treatment of colorectal cancer as single agents and in combination with conventional chemotherapy. Since the US Food and Drug Administration (FDA) had approved cetuximab in 2003 and panitumumab in 2006, EGFR antibodies have become primary step of treatment algorithms for colorectal cancer. However, nimotuzumab is a humanized monoclonal antibody that as of 2014 is recognized under orphan drugs status in the U.S. and the European Union for the treatment of glioma. This drug has also achieved marketing approval in India and China for squamaus cell carcinoma of the neck and head, and is currently undergoing numerous clinical trials.

Additionally, many market players and research institutions are performing research activities on development of the biosuperior EGFR antibodies against cancerous cells. The most common biosuperior EGFR antibodies include engineered EGFR antibodies, Bi- and Multi-specific EGFR antibodies and EGFR antibody drug conjugates. As for instance, Hoffmann-La Roche is performing a phase 1b study of MPDL3280A (and engineered antibody) in combination with Tarceva in patients suffering from non-small cell lung cancer. Such extensive research and development activities associated with the development of EGFR antibodies biosuperiors is the major factor which is driving this market. However, the high cost associated with research activities and sunk cost involved in R&D activities restrains the EGFR antibodies market.

Download Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7325

Moreover, the increasing incidence of cancer worldwide is also demanding for the more effective treatment methods, which is encouraging the researchers to develop EGFR antibodies. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. Lung, liver, colorectal, stomach and breast cancers were responsible for most of the deaths every year. Statistics also revealed that breast cancer incidence had risen by more than 20% in 2012 from 2009, while breast cancer mortality rate has increased by 14%. Due to harsh lifestyle, excessive intake of alcohol and smoking habits, the incidence of cancer is increasing rapidly worldwide, especially in developed economies of North America and Europe. Increasing morbidity and mortality rate among the cancer patients is fuelling the demand for EGFR antibodies, hence driving the market.

Some of the market players which are actively contributing towards EGFR antibodies market include Amgen, Inc., Eisai, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer, Inc., Biocon Ltd., Takeda Pharmaceutical Company, Ltd. and Immunogen, Inc.

Healthcare Information System Market: Challenges and Opportunities

The numbers emerging from the global healthcare information systems market could put the scope of opportunities in the market in a clearer perspective. This market was recorded at US$35.1 bn in 2013 and is expected to grow at a high rate till 2019, when it is projected to be valued at US$53.2 bn. To achieve this, the global healthcare information systems market should be expanding at a CAGR of 7.1% from 2013 to 2019. For a market that was already of a substantial size, this growth rate shows the promise of positive opportunities that perhaps even new entrants might find interesting.

From a player perspective, the global healthcare information systems market is being consistently led by GE Healthcare. It is also being spearheaded by names such as McKesson Corporation, Siemens Healthcare, Cerner Corporation, Epic Systems Corporation, and Philips Healthcare, among a few others. These are the names that other competitors need to pay attention to in order to make a mark in the global healthcare information systems market.

To do so, a market player will need the answers to three pertinent questions:

Is Integrated Healthcare System the Next Big Thing in the HIS Market?

To call integrated healthcare systems new would be slightly inaccurate; the use of a healthcare information system itself implies the scope for systems integration. As stated by Alain Enthoven, a professor of Public and Private Management, Emeritus, at the Graduate School of Business, the integration of systems in healthcare could easily help update doctors on the latest medical research, create interdisciplinary medical teams, and share medical histories with relevant members.

It could effectively lead to an organization cutting down healthcare costs by a noticeable amount. There is, therefore, an undoubted need for systems integration in the global healthcare information systems market, which is consequently one of the primary drivers that is boosting this market. There are other drivers as well, including increasing government and healthcare IT players’ initiatives, and growing aging population.

Does the Market Have a Workforce Strong Enough to Take up the Mounting Workload?

Unfortunately, the answer to this is currently no. The lack of experienced professionals is a worrisome trend in the global healthcare information systems market, but it is nothing that will dramatically stifle the market’s positive growth rate. The current scenario does show a shortage of medical personnel that are able to work in this field, but its future scope of growth will prove to be incentive enough for professionals to enter this field in larger numbers.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1457

Developed or Developing Markets: Where Should the Players Look? And Why?

There is not direct answer for this, but the answer will lie in the interest of the market player. North America has been the largest region in the global healthcare information systems market for a long time now, owing to a highly advanced healthcare industry, coupled with a much higher healthcare expenditure. This is a feasible field of development for top players that already have a base of operations in this region.

On the other hand, new entrants could look to Asia Pacific, which is the fastest-growing region in the global healthcare information systems market for the coming years. One of the key reasons for this is the growing adoption of home healthcare systems. Wireless medical electronics and cloud computing technologies have allowed for a much more convenient and cost-effective solution for patient care and data monitoring. This, in effect, becomes the main reason for the proliferation of the global healthcare information systems market in the developing markets.

Medical Laser Systems Market – Global Analysis Report, 2012 - 2018

The global medical laser systems market is dominated by North America. This regional market for medical laser systems is driven by the increasing prevalence of chronic disorders such as diabetes and obesity. Europe is another key regional market in the global medical laser systems market. On the other hand, it is Asia Pacific that is the most attractive region in the global medical laser systems market. This regional market offers the maximum opportunities for future growth.

The key factors driving the Asia Pacific medical laser systems market are the increasing disposable income and the high level of unmet medical needs in populous nations such as China and India. Broadly, the global medical laser systems market is segmented on the basis of product, application, and geography.

Besides offering a detailed analysis of the key regions, the study also offers an in-depth analysis of the key application and product segments. The leading segments of the global medical laser systems market and the fastest growing segments have also been evaluated in the report. The key trends driving these segments are also included. Moreover, the valuable forecasts of these segments are also covered.

Overview of the Global Medical Laser Systems Market

The global medical laser systems market is projected to expand at a 12.50% CAGR during the forecast period from 2012 to 2018. In 2011, the global medical laser systems market was worth US$0.9 bn and by 2018, the market is projected to be worth US$2.0 bn. The market is driven by the elevated rate of age-related ophthalmic disorders and the rising awareness related to medical aesthetics.

By product, the global medical laser systems market is segmented into diode laser systems, gas laser systems, solid state laser systems, and dye laser systems. The diode laser systems segment dominated the global medical laser systems market in 2011. Application-wise, the global medical laser systems market is divided into cardiovascular, dentistry, urology, gynecology, ophthalmology, dermatology, and others. By 2018, the cardiovascular segment is expected to emerge as the most rapidly developing application. The cardiovascular segment is driven by the development of affordable treatment methods and the rising prevalence of cardiovascular diseases.

Regionally, the global medical laser systems market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). In 2011, the global medical laser systems market was led by North America, followed by Europe. In 2011, North America held a dominant share of 35% in the global medical laser systems market.

Get a Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=324

Although the global medical laser systems market will expand notably in the coming few years, it will be suppressed by several factors. These include the high failure rates associated with medical laser systems, the implementation of the Affordable Care Act in the U.S., and stringent safety regulations in this market.

Companies mentioned in the research report

Players in the global medical laser systems market will benefit from the increasing level of disposable incomes in emerging economies. Some of the key players operating in the global medical laser systems market are PhotoMedex, Lumenis, Syneron Candela, AngioDynamics, BIOLASE, and American Medical Systems, Spectranetics Corporation.

The Emerging Role of Fragment-based Drug Discovery Market

Fragment-based drug discovery has been recognized as a potential method to design novel molecules as this technique discovery utilizes comparatively small libraries of ‘fragments or ligands’ that are of low-molecular weights. Factors such as less time-consumption and easy access to biophysical fragment screening techniques are driving the growth of the global fragment-based drug discovery market. However, certain factors such as lower level of potency in few compounds derived from fragment screening and requirement of unique ‘fragment libraries’ for performing the studies might pull back the growth of fragment-based drug discovery market.

Based on service component, the global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. Fragment screening segment dominated the market in 2014 due to high number of probable hit compounds identified through these techniques. Fragment screening segment is further categorized into biophysical and non-biophysical technique. Under the biophysical technique segment, nuclear magnetic resonance (NMR) spectroscopy held the majority market share in 2014. High sensitivity and moderate protein consumption of the method are the factors contributing to the high market share of the segment. However, the fluorescence polarization segment is expected to grow at the highest CAGR during the forecast period as this method requires the least maintenance, and shows rapid qualitative analysis of diverse molecular interactions.

The end-user segment in the fragment-based drug discovery market has been categorized into biopharmaceutical companies, CROs, and academic and research institutions. Biopharmaceutical companies was witnessed as the largest segment in terms of revenue in 2014. The segment is also expected to expand at the highest CAGR. The dominance of biopharmaceutical companies was attributed to increasing demand for fragment-based drug discovery in a number pharmaceutical companies for the identification of lead compounds in drug discovery process.

Geographically, North America accounted for the largest share of the global fragment-based drug discovery market in 2014. Factors attributed to the dominant position of North America in fragment-based drug discovery market are presence of a large number of pharmaceutical companies in the U.S. and ever-growing awareness of the population regarding fragment-based drug discovery market. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Key factors such as increasing research and development in various emerging economies, and greater demand for improved and modern healthcare infrastructures would accentuate the growth of fragment-based drug discovery market in Asia Pacific.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

The global fragment-based drug discovery market is fragmented due to the presence of numerous established as well as emerging players. The prominent companies operating in the fragment-based drug discovery market are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, BioFocus, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec AG, Kinetic Discovery, Proteros Fragments, Sprint Bioscience, Structure Based Design, and Sygnature Discovery.

A brief review of Radiopharmaceuticals Market

Radiopharmaceuticals are medicinal formulations containing radioisotopes that are found to be harmless for humans and can be safely administered for a therapy or diagnosis. Certain radiotracers (called radiopharmaceuticals), the chemical compounds with one or more atoms replaced by a radioisotope, have been traditionally used for imaging disease states and functional morphology of organs. Unlike other popular imaging modalities such as magnetic resonance imaging (MRI), ultrasonography (US), and computed tomography (CT), imaging procedures that use radiopharmaceuticals can also map metabolic activities and physiological functions, thereby giving more precise and specific information about function or dysfunction of an organ or metabolic activity.

Studying the use of radiotracers for therapeutic purposes had begun immediately after the discovery of radioactivity, however, it was not until cyclotrons became available for the acceleration of particles to fabricate radioisotopes that a significant medical application of radiotracers came into being. Radioiodine, for instance, was introduced in 1946 for treating thyroid cancer, and remains till date the most effective method for the treatment of the condition as well as hyperthyroidism.

Mapping the distribution of a radiopharmaceutical element in a body provides images of organ functions in a non-invasive manner and helps diagnose many common health conditions associated with malfunctioning organs as well as the detection of certain cancers. The extensive use and rising demand for imaging techniques that use radiopharmaceuticals are directly attributable to the enormous development observed in the global market for radiopharmaceuticals and has led to the availability of a huge range of specific radiopharmaceuticals.

Market Scenario

Currently, there are more than 100 radiopharmaceuticals in the global market, which are used for the diagnosis of a variety of diseases and for the therapy of a few, including cancer. Transparency Market Research, a U.S.-based market intelligence firm, states in one of its reports that the global radiopharmaceuticals market will grow at a remarkable CAGR of 18.3% between 2012 and 2018. The report also states that the market, which had a net worth of US$3.8 billion in 2011, will reach US$12.2 billion by 2018. Canada’s prominence in the global radiopharmaceuticals market as the largest exporter of uranium and nuclear technology has led the regional market in North America towards a position of dominance in the global marketplace.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213

While the market’s growth prospects are huge, the market faces a number of challenges that make exploitation of these opportunities a bit difficult. Elucidated below are some key challenges that the market for radiopharmaceuticals faces:

Low global production of Radiopharmaceuticals: Unlike the production of conventional pharmaceuticals, the production of radiopharmaceuticals still happens on a relatively small scale across the globe. Implementing the current good manufacturing practices (cGMP) guidelines in radiopharmaceutical manufacture is also a very difficult and expensive process. Ensuring cGMP compliances can especially become a demanding task for small-scale manufacturers.

Complex manufacturing cGMP code compliance: Manufacturing of radiopharmaceuticals involves taking care of a number of aspects prior to, during, and after the manufacturing process. It requires the use of controlled procedures and materials, qualified personnel to look after the entire process, production in designated clean rooms, detailed documentation of the process, application of analytical and validated methods, and the release of the final product by a qualified person.

Troubles and delays in transportation of radioactive substances: Transport of radioactive materials is a highly complex matter. Many troubles and delays, the need for obeying transport regulations, and the denial of shipment by certain transport bodies often affect the final use of imported radiopharmaceuticals. Some countries follow the practice of holding up all the cargo for 24 or 48 hours before loading it on the plane, for security purposes. This also leads to a negative effect on the overall properties of radiopharmaceuticals due to radioactive decay of the substance, especially in radioactive materials of extremely short half lives.